Refine
Has Fulltext
- yes (21)
Is part of the Bibliography
- yes (21)
Document Type
- Journal article (21)
Language
- English (21)
Keywords
- Fabry disease (7)
- echocardiography (4)
- enzyme replacement therapy (4)
- Enzyme replacement therapy (2)
- amyloidosis (2)
- cardiomyopathy (2)
- cardiovascular magnetic resonance (2)
- deformation (2)
- ejection fraction (2)
- fibrosis (2)
- lyso-Gb3 (2)
- myocardial infarction (2)
- prognosis (2)
- renal system (2)
- stroke (2)
- therapy (2)
- 2-dimensional speckle tracking (1)
- A-delta fibers (1)
- Agalsidase beta (1)
- Arterial Diameters (1)
- Cardiac magnetic resonance imaging (1)
- Cardiomyopathy (1)
- Cardiovascular magnetic-resonance (1)
- Chronic heart-failure (1)
- Chronic kidney disease (1)
- Coronary artery disease (1)
- Delphi procedure (1)
- Extracorporeal membrane oxygenation (1)
- Fabry (1)
- Female patients (1)
- GLA mutation (1)
- Guidelines (1)
- Hypertrophic cardiomyopathy (1)
- Kidney function (1)
- Lyso-Gb3 (1)
- Management (1)
- Manifestation (1)
- Myocardial fibrosis (1)
- Myocardial infarction (1)
- Pain-related evoked potentials (1)
- Prevalence (1)
- Prognostic impact (1)
- Quality of life (1)
- Risk-factors (1)
- SF-36 (1)
- Septal bulge (1)
- Small fiber neuropathy (1)
- Task force (1)
- Valvular heart-desease (1)
- Ventricular septal rupture (1)
- Ventricular-arrhythmias (1)
- agalsidase-beta (1)
- alpha-galactosidase-A (1)
- aneurysm (1)
- atypical (1)
- biomarker (1)
- biopsy (1)
- biopsy findings (1)
- blood flow (1)
- blood pressure monitoring (1)
- bull’s eye plot (1)
- calcium imaging (1)
- cardiac energy metabolism (1)
- cardiac magnetic resonance imaging (1)
- cardiac transplantation (1)
- cardiovascular magnetic-resonance (1)
- central nervous system (1)
- cerebral arteries (1)
- chronic thromboembolic pulmonary hypertension (1)
- clinical manifestations (1)
- death rates (1)
- diagnosis (1)
- diagnostic medicine (1)
- disease (1)
- fabry disease (1)
- females (1)
- focal semental glomerulosclerosis (1)
- follow-up (1)
- genotype (1)
- guidelines (1)
- heart disease (1)
- hypertension (1)
- hypertrophic cardiomyopathy (1)
- identification (1)
- immunofluorescence (1)
- impact (1)
- ischemic stroke (1)
- kidney (1)
- late-onset (1)
- left lateral wall (1)
- left ventricular hypertrophy (1)
- left ventricular thrombusv (1)
- left-ventricular hypertrophy (1)
- lesions (1)
- magnetic resonance imaging (1)
- mild (1)
- mortality (1)
- myocardial fibrosis (1)
- natural-history data (1)
- nerve fibers (1)
- neuropathy (1)
- podocyte (1)
- randomized controlled trial (1)
- recommendations (1)
- regression analysis (1)
- right ventricular dysfunction (1)
- skin diseases (1)
- speckle tracking imaging (1)
- statins (1)
- stem cell transplantation (1)
- surgical repair (1)
- tricuspid pressure gradient (1)
- troponin T (1)
- variant of unknown significance (1)
Institute
- Medizinische Klinik und Poliklinik I (16)
- Deutsches Zentrum für Herzinsuffizienz (DZHI) (6)
- Institut für diagnostische und interventionelle Radiologie (Institut für Röntgendiagnostik) (5)
- Neurologische Klinik und Poliklinik (5)
- Medizinische Klinik und Poliklinik II (2)
- Institut für Pharmakologie und Toxikologie (1)
- Klinik und Poliklinik für Thorax-, Herz- u. Thorakale Gefäßchirurgie (1)
- Medizinische Fakultät (1)
- Pathologisches Institut (1)
Sonstige beteiligte Institutionen
EU-Project number / Contract (GA) number
- 602133 (1)
Background
Fabry disease (FD) is an X-linked multisystemic disorder with a heterogeneous phenotype. Especially atypical or late-onset type 2 phenotypes present a therapeutical dilemma.
Methods
To determine the clinical impact of the alpha-Galactosidase A (GLA) p.A143T/ c.427G > A variation, we retrospectively analyzed 25 p.A143T patients in comparison to 58 FD patients with other missense mutations.
Results
p.A143T patients suffering from stroke/ transient ischemic attacks had slightly decreased residual GLA activities, and/or increased lyso-Gb3 levels, suspecting FD. However, most male p.A143T patients presented with significant residual GLA activity (~50 % of reference), which was associated with normal lyso-Gb3 levels. Additionally, p.A143T patients showed less severe FD-typical symptoms and absent FD-typical renal and cardiac involvement in comparison to FD patients with other missense mutations. Two tested female p.A143T patients with stroke/TIA did not show skewed X chromosome inactivation. No accumulation of neurologic events in family members of p.A143T patients with stroke/transient ischemic attacks was observed.
Conclusions
We conclude that GLA p.A143T seems to be most likely a neutral variant or a possible modifier instead of a disease-causing mutation. Therefore, we suggest that p.A143T patients with stroke/transient ischemic attacks of unknown etiology should be further evaluated, since the diagnosis of FD is not probable and subsequent ERT or chaperone treatment should not be an unreflected option.